INHIBRX BIOSCIENCES, INC. Increase (Decrease) in Accounts Payable
INHIBRX BIOSCIENCES, INC. (INBX) reported Increase (Decrease) in Accounts Payable of $3.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.01M.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.82M.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$829.00K.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.52M.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accounts payable for fiscal 2025 was -$3.30M, a 118.44% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accounts payable for fiscal 2024 was $17.90M, a 748.89% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accounts payable for fiscal 2023 was $2.11M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.83M 10-Q · filed 2026-08-13 | $3.00M derived: sum of 3 quarters · filed 2026-08-13 | $1.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.82M 10-Q · filed 2026-05-14 | $1.99M derived: sum of 2 quarters · filed 2026-05-14 | $470.00K derived: sum of 3 quarters · filed 2026-05-14 | -$130.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$829.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.35M derived: sum of 2 quarters · filed 2026-03-19 | -$2.95M derived: sum of 3 quarters · filed 2026-08-13 | -$3.30M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$2.12M derived: sum of 2 quarters · filed 2026-08-13 | -$2.47M 10-Q · filed 2025-11-14 | -$5.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$953.00K 10-Q · filed 2026-08-13 | -$4.07M derived: sum of 3 quarters · filed 2026-08-13 | -$4.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$353.00K 10-Q · filed 2026-05-14 | -$3.47M derived: sum of 2 quarters · filed 2026-05-14 | -$3.92M derived: sum of 3 quarters · filed 2026-05-14 | $13.50M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$3.57M derived: sum of 2 quarters · filed 2026-03-19 | $13.85M derived: sum of 3 quarters · filed 2026-03-19 | $17.90M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$450.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $16.97M derived: sum of 2 quarters · filed 2025-11-14 | $21.02M 10-Q · filed 2025-11-14 | $23.93M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $17.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $21.47M 10-Q · filed 2025-08-13 | $24.38M derived: sum of 3 quarters · filed 2025-08-13 | $22.79M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $4.05M 10-Q · filed 2025-05-14 | $6.96M derived: sum of 2 quarters · filed 2025-05-14 | $5.37M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.32M derived: sum of 2 quarters · filed 2025-03-17 | $2.11M 10-K · filed 2025-03-17 | |
| 2023-09-30 | -$1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$801.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $792.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |